In the last week, the Biotech industry is up 3.2%, with Sichuan Kelun-Biotech Biopharmaceutical leading the way, up 3.5%. Meanwhile, Cutia Therapeutics actually underperformed within the industry, shrinking 8.2% in the last week. In contrast, the industry has lost 32% in the last 12 months. Earnings are forecast to grow by 33% annually.
Has the Hong Kong Biotech Industry valuation changed over the past few years?
Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
---|---|---|---|---|---|---|
Sat, 03 Aug 2024 | HK$321.6b | HK$50.0b | -HK$19,621,133,103.77 | 11.6x | -16.4x | 6.4x |
Mon, 01 Jul 2024 | HK$327.6b | HK$49.6b | -HK$19,441,769,600.62 | 12.1x | -16.9x | 6.6x |
Wed, 29 May 2024 | HK$338.7b | HK$49.8b | -HK$19,505,887,561.30 | 11.3x | -17.4x | 6.8x |
Fri, 26 Apr 2024 | HK$346.9b | HK$49.5b | -HK$19,469,847,113.03 | 11.8x | -17.8x | 7x |
Sun, 24 Mar 2024 | HK$345.6b | HK$49.7b | -HK$19,699,938,439.12 | 14.1x | -17.5x | 7x |
Tue, 20 Feb 2024 | HK$329.9b | HK$46.8b | -HK$20,168,860,809.96 | 16.4x | -16.4x | 7.1x |
Thu, 18 Jan 2024 | HK$354.3b | HK$46.8b | -HK$20,184,432,385.00 | 17x | -17.6x | 7.6x |
Sat, 16 Dec 2023 | HK$406.3b | HK$47.2b | -HK$20,376,104,618.00 | 17.9x | -19.9x | 8.6x |
Mon, 13 Nov 2023 | HK$417.3b | HK$45.2b | -HK$18,924,858,618.00 | 13.5x | -22.1x | 9.2x |
Wed, 11 Oct 2023 | HK$380.4b | HK$44.9b | -HK$19,115,913,057.00 | 13.3x | -19.9x | 8.5x |
Fri, 08 Sep 2023 | HK$400.2b | HK$44.9b | -HK$18,889,389,617.00 | 15.3x | -21.2x | 8.9x |
Sun, 06 Aug 2023 | HK$398.2b | HK$35.6b | -HK$23,393,254,800.00 | 22.3x | -17x | 11.2x |
Tue, 04 Jul 2023 | HK$392.4b | HK$35.3b | -HK$23,202,884,962.00 | 25.7x | -16.9x | 11.1x |
Thu, 01 Jun 2023 | HK$412.8b | HK$35.9b | -HK$23,645,687,154.00 | 26.8x | -17.5x | 11.5x |
Sat, 29 Apr 2023 | HK$445.1b | HK$36.9b | -HK$23,365,935,236.00 | 17.8x | -19.1x | 12.1x |
Mon, 27 Mar 2023 | HK$430.5b | HK$35.1b | -HK$35,058,747,287.00 | 22.5x | -12.3x | 12.3x |
Wed, 22 Feb 2023 | HK$417.7b | HK$34.5b | -HK$34,860,112,837.00 | 33.1x | -12x | 12.1x |
Fri, 20 Jan 2023 | HK$449.5b | HK$34.9b | -HK$35,241,637,476.00 | 29.4x | -12.8x | 12.9x |
Sun, 18 Dec 2022 | HK$394.6b | HK$33.6b | -HK$33,868,975,451.00 | 24.3x | -11.7x | 11.8x |
Tue, 15 Nov 2022 | HK$375.3b | HK$33.2b | -HK$33,509,711,772.00 | 17.2x | -11.2x | 11.3x |
Thu, 13 Oct 2022 | HK$274.0b | HK$33.8b | -HK$32,318,825,304.00 | 15.6x | -8.5x | 8.1x |
Sat, 10 Sep 2022 | HK$355.8b | HK$34.3b | -HK$33,625,291,716.00 | 17x | -10.6x | 10.4x |
Mon, 08 Aug 2022 | HK$337.2b | HK$32.8b | -HK$46,282,522,083.00 | 12.1x | -7.3x | 10.3x |
Wed, 06 Jul 2022 | HK$382.7b | HK$33.1b | -HK$46,626,033,002.00 | 15.1x | -8.2x | 11.6x |
Fri, 03 Jun 2022 | HK$323.7b | HK$34.2b | -HK$46,119,353,466.00 | 13.1x | -7x | 9.5x |
Sun, 01 May 2022 | HK$337.9b | HK$35.5b | -HK$44,796,407,626.00 | 13.3x | -7.5x | 9.5x |
Tue, 29 Mar 2022 | HK$328.9b | HK$36.1b | -HK$38,875,100,995.00 | 13.2x | -8.5x | 9.1x |
Thu, 24 Feb 2022 | HK$331.0b | HK$33.0b | -HK$31,387,875,444.00 | 13.2x | -10.5x | 10x |
Sat, 22 Jan 2022 | HK$361.7b | HK$31.2b | -HK$31,905,520,771.00 | 13.1x | -11.3x | 11.6x |
Mon, 20 Dec 2021 | HK$427.4b | HK$31.1b | -HK$31,807,684,351.00 | 13.6x | -13.4x | 13.8x |
Wed, 17 Nov 2021 | HK$499.8b | HK$31.0b | -HK$31,715,065,788.00 | 13.9x | -15.8x | 16.1x |
Fri, 15 Oct 2021 | HK$494.8b | HK$30.6b | -HK$31,600,234,295.00 | 14.5x | -15.7x | 16.2x |
Sun, 12 Sep 2021 | HK$528.3b | HK$30.4b | -HK$31,412,511,864.39 | 17.6x | -16.8x | 17.4x |
Tue, 10 Aug 2021 | HK$579.3b | HK$30.2b | -HK$32,058,827,347.35 | 14.6x | -18.1x | 19.2x |
-18.1x
Which industries have driven the changes within the Hong Kong Healthcare industry?
HK Market | -0.018% | |
Healthcare | 1.13% | |
Biotech | 2.40% | |
Biotech | 2.40% |
Which companies have driven the market over the last 7 days?
Company | Last Price | 7D | 1Y | Valuation | |
---|---|---|---|---|---|
6990 Sichuan Kelun-Biotech Biopharmaceutical | HK$154.60 | 3.5% +HK$1.2b | 108.9% | PS20.6x | |
9926 Akeso | HK$42.00 | 3.3% +HK$1.2b | 15.1% | PE16.5x | |
1541 ImmuneOnco Biopharmaceuticals (Shanghai) | HK$14.92 | 15.7% +HK$755.8m | n/a | PS657.5x | |
1877 Shanghai Junshi Biosciences | HK$12.12 | 5.8% +HK$650.0m | -48.0% | PS6.8x | |
1801 Innovent Biologics | HK$39.25 | 0.9% +HK$569.9m | 19.7% | PS9.5x |